Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017 – 2018 season

References

• Raviotta JM, Smith KJ, DePasse J, et al. Cost-effectiveness and public health effect of influenza vaccine strategies for U.S. elderly adults. J Am Geriatr Soc. 2016 Oct;64(10):2126–2131. Epub 2016 Oct 6.
   PubMed Web of Science ®Google Scholar
• Putri WCWS, Muscatello DJ, Stockwell MS, et al. Economic burden of seasonal influenza in the United States. Vaccine. 2018 Jun 22;36(27):3960–3966. Epub 2018 May 22.
   PubMed Web of Science ®Google Scholar
• Ministry of Health. Recommendations for Influenza Prevention and Control, 2017–2018 Season. Italy. [cited 2019 Mar 13]. Available at: http://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2017&codLeg=60180&parte=1%20&serie=null
   Google Scholar
• Ministry of Health. Influenza Vaccine Coverage Data. [cited 2019 Mar 13]. Available from: http://www.salute.gov.it/portale/influenza/dettaglioContenutiInfluenza.jsp?lingua=italiano&id=679&area=influenza&menu=vuoto
   Google Scholar
• National Institute of Health. InfluNet. Epidemiological Report of the 2017/2018 Season. Italy. [cited 2019 Mar 13]. Available at: http://www.epicentro.iss.it/problemi/influenza/pdf/Rapporto%20InfluNet%202018-17.pdf
   Google Scholar
• Rizzo C, Viboud C, Montomoli E, et al. Influenza-related mortality in the Italian elderly: no decline associated with increasing vaccination coverage. Vaccine. 2006 Oct 30;24(42–43):6468–6475. Epub 2006 Jul 7.
   PubMed Web of Science ®Google Scholar
• Simonsen L, Reichert TA, Viboud C, et al. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med. 2005 Feb 14;165(3):265–272.
   PubMed Web of Science ®Google Scholar
• Michiels B, Govaerts F, Remmen R, et al. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine. 2011;29:9159–9170. PMID:21840359.
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Viboud C, et al. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis. 2007 Oct;7(10):658–666.
   PubMed Web of Science ®Google Scholar
• Saurwein-Teissl M, Lung TL, Marx F, et al. Lack of antibody production following immunization in old age: association with CD8(+)CD28(−) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol Baltim Md: 1950. 2002;168:5893–5899. Haq K, McElhaney JE. Immunosenescence: Influenza vaccination and the elderly. Curr Opin Immunol 2014; 29:38–42;PMID:24769424.
   Google Scholar
• Jefferson T, Di Pietrantonj C, Al-Ansary LA, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010;17:CD004876. PMID:20166072.
   Google Scholar
• Wong K, Campitelli MA, Stukel TA, et al. Estimating influenza vaccine effectiveness in community-dwelling elderly patients using the instrumental variable analysis method. Arch Intern Med. 2012 Mar 26;172(6):484–491. Epub 2012 Feb 27.
   PubMedGoogle Scholar
• Havers F, Sokolow L, Shay DK, et al. Case-control study of vaccine effectiveness in preventing laboratory-confirmed influenza hospitalizations in older adults, United States, 2010–2011. Clin Infect Dis. 2016 Nov 15;63(10):1304–1311. Epub 2016 Aug 2.
   PubMed Web of Science ®Google Scholar
• Chen Q, Griffin MR, Nian H, et al. Influenza vaccine prevents medically attended influenza-associated acute respiratory illness in adults aged ≥50 years. J Infect Dis. 2015 Apr 1;211(7):1045–1050. Epub 2014 Oct 21.
   PubMed Web of Science ®Google Scholar
• Seqirus Announces Shipment of FLUADTM (Influenza Vaccine, Adjuvanted) in the US for 2016–2017 flu Season. [cited 2019 Mar 15]. Available from: https://www.seqirus-us.com/news-room/Seqirus-announces-shipment-of-FLUAD-in-the-US-for-2016-2017-flu-season
   Google Scholar
• Noh JY, Song JY, Choi WS, et al. Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines. Hum Vaccin Immunother. 2016 Nov;12(11):2902–2908.
   PubMed Web of Science ®Google Scholar
• Camilloni B, Basileo M, Valente S, et al. Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: a literature review. Hum Vaccin Immunother. 2015;11(3):553–563.
   PubMed Web of Science ®Google Scholar
• Domnich A, Arata L, Amicizia D, et al. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis. Vaccine. 2017 Jan 23;35(4):513–520. Epub 2016 Dec 23.
   PubMed Web of Science ®Google Scholar
• Rondy M, Larrauri A, Casado I, et al.; I-MOVE+ Hospital working group. 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project. Euro Surveill. 2017 Jul 27;22((30).pii):30580.
   PubMedGoogle Scholar
• Kissling E, Rondy M; I-MOVE/I-MOVE+ study team. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. Euro Surveill. 2017 Feb 16; 22(7.pii):30464.
   PubMedGoogle Scholar
• Rondy M, Gherasim A, Casado I, et al.; I-MOVE+ hospital working group. Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season. Euro Surveill. 2017 Oct;22(41). DOI:10.2807/1560-7917.ES.2017.22.41.17-00645.
   Google Scholar
• World Health Organization. Global Epidemiological Surveillance Standards for Influenza. [cited 2019 Mar 15]. Available from: WHO_Epidemiological_Influenza_Surveillance_Standards_2014.pdf
   Google Scholar
• Rondy M, Kissling E, Emborg HD, et al.; I-MOVE/I-MOVE+ group. Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies. Euro Surveill. 2018 Mar;23(9). DOI:10.2807/1560-7917.ES.2018.23.9.18-00086.
   PubMedGoogle Scholar
• National Influenza Surveillance Scheme. Flunews-Italy weekly report. [cited 2019 Mar 15]. Available from: http://www.epicentro.iss.it/influenza/FluNews17-18
   Google Scholar
• Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942–951. PMID: 27061888.
   PubMed Web of Science ®Google Scholar
• Flannery B, Chung JR, Belongia EA, et al. Interim estimates of 2017–18 seasonal influenza vaccine effectiveness - United States, February 2018. MMWR Morb Mortal Wkly Rep. 2018;67(6):180–185. PMID: 29447141.
   PubMed Web of Science ®Google Scholar
• Castilla J, Navascués A, Casado I, et al. Interim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza B, northern Spain, 2017/18. Euro Surveill. 2018;23(7):18–00057. PMID: 29471624.
   Google Scholar
• Skowronski DM, Chambers C, De Serres G, et al. Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018. Euro Surveill. 2018;23(5):18–00035. PMID: 29409570.
   Google Scholar
• Camilloni B, Basileo M, Di Martino A, et al. Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strains. Immun Ageing. 2014;11:10.
   PubMed Web of Science ®Google Scholar
• Baldo V, Baldovin T, Pellegrini M, et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol. 2010;2010:517198.
   PubMedGoogle Scholar
• Camilloni B, Neri M, Lepri E, et al. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. Vaccine. 2009;27:4099–4103.
   PubMed Web of Science ®Google Scholar
• Ray R, Dos Santos G, Buck PO, et al. A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control. Hum Vaccin Immunother. 2017;13(7):1640–1652.
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Chambers C, De Serres G, et al. Vaccine effectiveness against lineage matched and mismatched influenza B viruses across 8 seasons in Canada, 2010–11 to 2017–18. Clin Infect Dis. 2018. DOI:10.1093/cid/ciy876.
   Google Scholar
• Beyer WEP, Palache AM, Boulfich M, et al. Rationale for two influenza B lineages in seasonal vaccines: a meta-regression study on immunogenicity and controlled field trials. Vaccine. 2017;35(33):4167–4176.
   PubMed Web of Science ®Google Scholar
• National Institute of Health, National Influenza Center. InfluNet, Virological Report of the 2017/2018 season. Italy. [cited 2019 Mar 15]. Available from: http://old.iss.it/binary/fluv/cont/Sorveglianza_20virologica_20dell_influenza_20rapporto_20stagione_202017_2018.pdf
   Google Scholar